CoChat

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Background: Molecular mechanisms driving acquired resistance to anti-EGFR therapies in metastatic colorectal cancer (mCRC) are complex but generally involve the activation of the downstream RAS-RAF-MEK-MAPK pathway. Nevertheless, even if inhibition of EGFR and MEK could be a strategy for overcoming anti-EGFR resistance, its use is limited by the development of MEK inhibitor (MEKi) resistance. Methods: We have generated in vitro and in vivo different CRC models in order to underline the mechanisms of MEKi resistance. Results: The three different in vitro MEKi resistant models, two generated by human CRC cells quadruple wild type for KRAS, NRAS, BRAF, PI3KCA genes (SW48-MR and LIM1215-MR) and one by human CRC cells harboring KRAS mutation (HCT116-MR) showed features related to the gene signature of colorectal cancer CMS4 with up-regulation of immune pathway as confirmed by microarray and western blot analysis. In particular, the MEKi phenotype was associated with the loss of epithelial features and acquisition of mesenchymal markers and morphology. The change in morphology was accompanied by up-regulation of PD-L1 expression and activation of EGFR and its downstream pathway, independently to RAS mutation status. To extend these in vitro findings, we have obtained mouse colon cancer MC38- and CT26-MEKi resistant syngeneic models (MC38-MR and CT26-MR). Combined treatment with MEKi, EGFR inhibitor (EGFRi) and PD-L1 inhibitor (PD-L1i) resulted in a marked inhibition of tumor growth in both models. Conclusions: These results suggest a strategy to potentially improve the efficacy of MEK inhibition by co-treatment with EGFR and PD-L1 inhibitors via modulation of host immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-019-1497-0

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CMS4 gene expression signature in a preclinical model of colon cancer cells with acquired resistance to MEKi. Agilent microarray analyses were performed to assess baseline gene expression profile for SW48 and SW48-MR Colon cancer cell lines, as described in Materials and Methods. (Log) fold change indicates relative microRNA expression levels in SW48-MR respect to SW48 cells. The genes whose expression is up regulated in SW48-MR compared to SW48 cells are represented in schematic tables. These genes are involved in CMS4 gene signature
Fig. 1 CMS4 gene expression signature in a preclinical model of colon cancer cells with acquired resistance to MEKi. Agilent microarray analyses were performed to assess baseline gene expression profile for SW48 and SW48-MR Colon cancer cell lines, as described in Materials and Methods. (Log) fold change indicates relative microRNA expression levels in SW48-MR respect to SW48 cells. The genes whose expression is up regulated in SW48-MR compared to SW48 cells are represented in schematic tables. These genes are involved in CMS4 gene signatureCC BY · PubMed Central
Fig. 2 Establishment and characterization of MEKi-resistant human colorectal cancer cell lines. a-c. Total cell protein extracts (50 μg) were subjected to immunoblotting with the indicated antibodies, as described in Materials and Methods. Anti-tubulin antibody was used for normalization of protein extract content. Experiments were repeated three times. b. HCT116 and HCT116-MR Cells were treated with different concentrations of BAY86–9766 (0.01–10 μM) for 96 h and evaluated for proliferation by MTT staining, as described in Materials and Methods. The results are the average ± SD of three independent experiments each done in triplicate. d. Morphologic change in resistant cell lines compared to parental cell lines
Fig. 2 Establishment and characterization of MEKi-resistant human colorectal cancer cell lines. a-c. Total cell protein extracts (50 μg) were subjected to immunoblotting with the indicated antibodies, as described in Materials and Methods. Anti-tubulin antibody was used for normalization of protein extract content. Experiments were repeated three times. b. HCT116 and HCT116-MR Cells were treated with different concentrations of BAY86–9766 (0.01–10 μM) for 96 h and evaluated for proliferation by MTT staining, as described in Materials and Methods. The results are the average ± SD of three independent experiments each done in triplicate. d. Morphologic change in resistant cell lines compared to parental cell linesCC BY · PubMed Central
Fig. 3 Effect of STAT3 inhibition on PD-L1 and EGFR expression in HCT116-MR colon cancer cells. a. The mRNA expression levels of STAT3, PD-L1 and EGFR 24 h, 48 h, and 72 h after transfection with a specific siRNA targeting STAT3 in HCT116-MR cells. One way anova test: *p < 0.05, ***p < 0.001 compared with the control. b. Western blot analysis of cell signalling proteins in HCT116-MR cells transfected with a specific siRNA targeting STAT3 or with a scrambled, control siRNA for 24, 48 and 72 h. Total cell protein extracts were subjected to immune-blotting with the indicated antibodies, as described in Materials and Methods. c. HCT116-MR cells were transfected with siRNA targeting STAT3. 72 h after transfection, cells were treated with increasing concentrations of MEKi (BAY86–9766, range 0–15 μM). Cells were evaluated for proliferation after 48 h by MTT staining. The results are average ± SD of three independent experiments each done in duplicate. d. The mRNA expression levels of STAT3, PD-L1 and EGFR with a specific siRNA targeting STAT3 or with a scrambled, control siRNA for 72 h and subsequently treated with the indicated dose of MEKi (BAY86–9766) treatment for 24 h. One way anova test: *p < 0.05, ***p < 0.001 compared with the control
Fig. 3 Effect of STAT3 inhibition on PD-L1 and EGFR expression in HCT116-MR colon cancer cells. a. The mRNA expression levels of STAT3, PD-L1 and EGFR 24 h, 48 h, and 72 h after transfection with a specific siRNA targeting STAT3 in HCT116-MR cells. One way anova test: *p < 0.05, ***p < 0.001 compared with the control. b. Western blot analysis of cell signalling proteins in HCT116-MR cells transfected with a specific siRNA targeting STAT3 or with a scrambled, control siRNA for 24, 48 and 72 h. Total cell protein extracts were subjected to immune-blotting with the indicated antibodies, as described in Materials and Methods. c. HCT116-MR cells were transfected with siRNA targeting STAT3. 72 h after transfection, cells were treated with increasing concentrations of MEKi (BAY86–9766, range 0–15 μM). Cells were evaluated for proliferation after 48 h by MTT staining. The results are average ± SD of three independent experiments each done in duplicate. d. The mRNA expression levels of STAT3, PD-L1 and EGFR with a specific siRNA targeting STAT3 or with a scrambled, control siRNA for 72 h and subsequently treated with the indicated dose of MEKi (BAY86–9766) treatment for 24 h. One way anova test: *p < 0.05, ***p < 0.001 compared with the controlCC BY · PubMed Central
Fig. 4 Effect of PD-L1 inhibition on STAT3 and EGFR expression in HCT116-MR colon cancer cells. a. The mRNA expression levels of PD-L1, STAT3 and EGFR at 24 h, 48 h, and 72 h after transfection with a specific siRNA targeting PD-L1. One way anova test: **p < 0.002; ****p < 0.0001 compared with the control. b. Western blot analysis of cell signalling proteins in HCT116-MR cells transfected with a specific siRNA targeting PD-L1 or with a scrambled, control siRNA for 24, 48 and 72 h. Total cell protein extracts were subjected to immune-blotting with the indicated antibodies, as described in Materials and Methods
Fig. 4 Effect of PD-L1 inhibition on STAT3 and EGFR expression in HCT116-MR colon cancer cells. a. The mRNA expression levels of PD-L1, STAT3 and EGFR at 24 h, 48 h, and 72 h after transfection with a specific siRNA targeting PD-L1. One way anova test: **p < 0.002; ****p < 0.0001 compared with the control. b. Western blot analysis of cell signalling proteins in HCT116-MR cells transfected with a specific siRNA targeting PD-L1 or with a scrambled, control siRNA for 24, 48 and 72 h. Total cell protein extracts were subjected to immune-blotting with the indicated antibodies, as described in Materials and MethodsCC BY · PubMed Central
Fig. 5 Expression of PD-L1 and EGFR by immunofluorescence analysis. a. Immunofluorescence analysis of the localization of EGFR and PD-L1 in HCT116 and HCT116-MR cells after exposure to different time of TGFα (5 min, 20 min and 1 h). Cells were stained with anti-EGFR antibody followed by secondary antibody labeled with Alexa Fluor 488 and anti-PD-L1 antibody followed by secondary antibody Alexa Fluor 532. DAPI was included to stain the nucleus. b. Cytofluorimetric analysis of HCT116 MR cells. Cells are stimulated with TGFα for 5 min, 20 min and 1 h alone or in combination with MEKi (BAY86–9766 0,5 μM) and then we investigated the presence of EGFR and PD-L1 on the surface of cells. c. An upregulation of PD-L1 is observed in the nucleus of HCT116 MR cells. Green color from Alexa Fluor 488 for PD-L1 and blue color from DAPI for visualization of nuclei. d. HCT116 and HCT116-MR were lysed to obtain cytosolic and nuclear fragments that were analyzed by Western blot analysis. Tubulin and Histone H3 antibodies were used as loading and purity control of the cytosolic and nuclear fractions, respectively
Fig. 5 Expression of PD-L1 and EGFR by immunofluorescence analysis. a. Immunofluorescence analysis of the localization of EGFR and PD-L1 in HCT116 and HCT116-MR cells after exposure to different time of TGFα (5 min, 20 min and 1 h). Cells were stained with anti-EGFR antibody followed by secondary antibody labeled with Alexa Fluor 488 and anti-PD-L1 antibody followed by secondary antibody Alexa Fluor 532. DAPI was included to stain the nucleus. b. Cytofluorimetric analysis of HCT116 MR cells. Cells are stimulated with TGFα for 5 min, 20 min and 1 h alone or in combination with MEKi (BAY86–9766 0,5 μM) and then we investigated the presence of EGFR and PD-L1 on the surface of cells. c. An upregulation of PD-L1 is observed in the nucleus of HCT116 MR cells. Green color from Alexa Fluor 488 for PD-L1 and blue color from DAPI for visualization of nuclei. d. HCT116 and HCT116-MR were lysed to obtain cytosolic and nuclear fragments that were analyzed by Western blot analysis. Tubulin and Histone H3 antibodies were used as loading and purity control of the cytosolic and nuclear fractions, respectivelyCC BY · PubMed Central
Fig. 6 Effects of combined treatment of MEK inhibitor, EGFR inhibitor and PD-L1 inhibitor on syngeneic colorectal cancer tumor xenograft models with acquired resistance to MEKi. a. C57BL/6 and BALB/c immune-competent mice were injected subcutaneously in the right flank with MC38-MR and CT26-MR cells as described in the Materials and Methods. After two weeks (average tumor size 200–300 mm3) mice were treated with: PBS (phosphate-buffered saline) as control, MEKi (BAY86–9766 25 mg/kg every day for 5 days a week, by oral gavage), EGFRi (erlotinib 10 mg/Kg every day for 5 days a week by oral gavage), mouse PD-L1i (clone 10F.9G2) injected twice a week i.p. at total dose of 200 μg/mouse, MEKi+PD-L1i at doses described above and MEKi+EGFRi+PD-L1i at doses described above. The treatment was continued for 3 weeks. Mice were followed for additional 5 weeks. Each group consisted of 10 mice. The mean data are present. Tumor growth curves were calculated based on twice weekly times tumor measurements during the treatment period and after 5 weeks of observation after termination of therapy. Animals were sacrificed when tumors achieved 2.000 mm3 in size. b. At the end of treatment one mouse per group treated with MEKi, EGFRi, PD-L1i or with their combination was sacrificed. As control, we used one mouse engraft with MC38-MR and CT26-MR respectively that has not undergone to any type of treatment. Tumor samples were collected and total cell protein extracts were subjected to immunoblotting with the indicated antibodies, as described in Materials and Methods. Anti-tubulin antibody was used for normalization of protein extract content
Fig. 6 Effects of combined treatment of MEK inhibitor, EGFR inhibitor and PD-L1 inhibitor on syngeneic colorectal cancer tumor xenograft models with acquired resistance to MEKi. a. C57BL/6 and BALB/c immune-competent mice were injected subcutaneously in the right flank with MC38-MR and CT26-MR cells as described in the Materials and Methods. After two weeks (average tumor size 200–300 mm3) mice were treated with: PBS (phosphate-buffered saline) as control, MEKi (BAY86–9766 25 mg/kg every day for 5 days a week, by oral gavage), EGFRi (erlotinib 10 mg/Kg every day for 5 days a week by oral gavage), mouse PD-L1i (clone 10F.9G2) injected twice a week i.p. at total dose of 200 μg/mouse, MEKi+PD-L1i at doses described above and MEKi+EGFRi+PD-L1i at doses described above. The treatment was continued for 3 weeks. Mice were followed for additional 5 weeks. Each group consisted of 10 mice. The mean data are present. Tumor growth curves were calculated based on twice weekly times tumor measurements during the treatment period and after 5 weeks of observation after termination of therapy. Animals were sacrificed when tumors achieved 2.000 mm3 in size. b. At the end of treatment one mouse per group treated with MEKi, EGFRi, PD-L1i or with their combination was sacrificed. As control, we used one mouse engraft with MC38-MR and CT26-MR respectively that has not undergone to any type of treatment. Tumor samples were collected and total cell protein extracts were subjected to immunoblotting with the indicated antibodies, as described in Materials and Methods. Anti-tubulin antibody was used for normalization of protein extract contentCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 44

Metadata

Authors
Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., Furia, M., Kopetz, S., Morgillo, F., Ciardiello, F., & Troiani, T.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Campania "Luigi Vanvitelli" (IT)
  • University of Naples Federico II (IT)
Corresponding author
Troiani, T.
Venue
Journal of Experimental & Clinical Cancer Research
Published
2019-12
Volume
38
Issue
1
Pages
492-492
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W2995994395
Cited by
40
References
51
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 4
FWCI
2.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by)
Funders
  • Associazione Italiana per la Ricerca sul Cancro (AIRC IG 18972)
  • Regione Campania (I-CURE)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
MEK inhibitor resistance, EGFR inhibition, PD-L1 blockade, metastatic colorectal cancer, MAPK signaling, PD-L1 overexpression, mesenchymal transition, tumor immune microenvironment, anti-EGFR resistance, combination therapy, syngeneic mouse model
MeSH terms
Erlotinib Hydrochloride, Antibodies, Monoclonal, Diphenylamine, Female, Humans, Sulfonamides, Colorectal Neoplasms, Treatment Outcome, Drug Resistance, Neoplasm, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Epithelial-Mesenchymal Transition, B7-H1 Antigen, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. https://app.cochat.ai/papers/10.1186/s13046-019-1497-0
The paper
Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., Furia, M., Kopetz, S., Morgillo, F., Ciardiello, F., & Troiani, T. (2019). Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-019-1497-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.